Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRYSTAL-1: ORX750 in Narcolepsy and Idiopathic Hypersomnia
2024-518929-15-00Phase 2Authorised
- Sponsor
- Centessa Pharmaceuticals
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial in narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and hypersomnolence disorder comparing ORX750 with Placebo (2 arms). Primary endpoint: Safety and tolerability. Planned start May 2025; status: authorised.
02
Drugs
cleminorexton
03
Conditions
narcolepsy type 1 (NT1)narcolepsy type 2 (NT2)hypersomnolence disorder
Beyond the preview
Go deeper on 2024-518929-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518929-15-00.